The most common question I get from people who’ve just started researching GLP-1 medications is some version of: “What’s the difference between Ozempic and Wegovy? Should I be on one instead of the other?”
The short answer is they’re the same drug at different doses with different FDA approvals. The longer answer matters for what you’ll actually be able to get, what it costs, and what your options are if one isn’t available.
Same Drug, Different Label
Ozempic and Wegovy both contain semaglutide. That’s the active ingredient. Novo Nordisk makes both of them. They work through the same mechanism: binding to GLP-1 receptors to reduce hunger and slow gastric emptying.
The differences:
- FDA indication: Ozempic is approved for type 2 diabetes. Wegovy is approved for chronic weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition.
- Maximum dose: Ozempic goes up to 2mg weekly. Wegovy goes up to 2.4mg weekly.
- Dosing schedule: Both start low and increase gradually over months.
When a doctor prescribes Ozempic for weight loss, they’re prescribing it off-label. That’s legal and common. The drug works the same way at comparable doses.
Which One Produces More Weight Loss?
The STEP 1 trial, which used 2.4mg semaglutide weekly (the Wegovy dose), showed average weight loss of 14.9% over 68 weeks. Studies using Ozempic at its maximum 2mg dose show slightly lower average results, though the difference is modest.
In practice, the dose matters more than the brand name. A doctor who prescribes Ozempic off-label for weight loss will typically follow the same dose escalation protocol used in the Wegovy trials.
Cost Comparison
Both are expensive without insurance. Wegovy typically retails for $1,300 to $1,600 per month without coverage. Ozempic runs $900 to $1,000 per month.
Insurance coverage is where things get complicated. Wegovy is more likely to be covered under plans that include weight management benefits, because it has the on-label indication. Ozempic prescribed for weight loss is off-label and often denied.
Novo Nordisk offers savings cards for both medications, but eligibility varies and savings are typically capped.
The most cost-effective route for most people without coverage is compounded semaglutide through a telehealth provider. Compounded versions are not brand-name Ozempic or Wegovy, but they contain the same active ingredient at significantly lower cost, typically $200 to $400 per month.
What About Mounjaro and Zepbound?
Worth mentioning because this comparison comes up constantly. Mounjaro and Zepbound contain tirzepatide, made by Eli Lilly. Tirzepatide is a dual agonist: it targets both GLP-1 and GIP receptors.
The SURMOUNT trials showed tirzepatide producing higher average weight loss than semaglutide. Participants on the highest dose lost an average of 22.5% of body weight over 72 weeks.
Again, these are averages. Some people do better on semaglutide. Some can’t tolerate tirzepatide’s side effects. The best option depends on your response, not just the clinical averages.
Which Should You Choose?
If you’re going through insurance: apply for Wegovy if you have weight management benefits, since the on-label indication is easier to get covered.
If you’re going through telehealth without insurance: the distinction matters less. Telehealth providers typically offer compounded semaglutide or compounded tirzepatide, and the choice comes down to dosing, pricing, and how your body responds.
If you’re comparing programs, GobyMeds offers a straightforward evaluation process and transparent pricing. Use code MTVN25 for $25 off your first order. I earn a commission if you use that link.
For a full breakdown of how to access GLP-1 medication, read: How to Get GLP-1 Medication Online
Judy White is the founder of Motivation Weight Loss. She used GLP-1 injections as part of her own weight loss and writes from personal experience, not as a medical professional.